Activity of Tigecycline or Colistin in Combination with Zidovudine against Escherichia coli Harboring tet(X) and mcr-1.
Yu-Feng ZhouPing LiuShu-He DaiJian SunYa-Hong LiuXiao-Ping LiaoPublished in: Antimicrobial agents and chemotherapy (2020)
Alternative therapeutic options are urgently needed against multidrug-resistant Escherichia coli infections, especially in situations of preexisting tigecycline and colistin resistance. Here, we investigated synergistic activity of the antiretroviral drug zidovudine in combination with tigecycline or colistin against E. coli harboring tet(X) and mcr-1 in vitro and in a murine thigh infection model. Zidovudine and tigecycline/colistin combinations achieved synergistic killing and significantly decreased bacterial burdens by >2.5-log10 CFU/g in thigh tissues compared to each monotherapy.
Keyphrases
- klebsiella pneumoniae
- escherichia coli
- multidrug resistant
- acinetobacter baumannii
- drug resistant
- gram negative
- biofilm formation
- pseudomonas aeruginosa
- cancer therapy
- human immunodeficiency virus
- hiv infected
- combination therapy
- soft tissue
- randomized controlled trial
- cystic fibrosis
- hepatitis c virus
- staphylococcus aureus
- adverse drug